Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Presents Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Showing No Significant Effects on Blood Pressure or Heart Rate
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
11:36am, Friday, 10'th Sep 2021
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
3 Stocks Insiders Are Buying
06:11am, Tuesday, 07'th Sep 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the Virtual 2021 Annual Meeting of the American Urological Association
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
08:30am, Wednesday, 01'st Sep 2021
BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global
Here's Why Myovant Sciences Stock Is Falling Today
02:47pm, Wednesday, 28'th Jul 2021
Second-quarter earnings results were a little bit disappointing.
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2021 Results - Earnings Call Transcript
12:05pm, Wednesday, 28'th Jul 2021
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2021 Results - Earnings Call Transcript
Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates
09:54am, Wednesday, 28'th Jul 2021
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Myovant Sciences Q1 Earnings
07:36am, Wednesday, 28'th Jul 2021
Shares of Myovant Sciences (NYSE:MYOV) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 81.08% year over year to ($0.67), which mis
Europe OK's Myovant's Relugolix Combo Therapy For Uterine Fibroids
06:38am, Tuesday, 20'th Jul 2021
The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe sym
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
02:00am, Tuesday, 20'th Jul 2021
BASEL, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (E
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
10:31am, Thursday, 01'st Jul 2021
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
03:23pm, Thursday, 24'th Jun 2021
This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
Myovant and Partner Get Key Drug Approval
02:34pm, Wednesday, 16'th Jun 2021
A lesser-known British biotech is among eight pharma companies the publication Kiplinger encouraged readers to monitor for important key clinical trial results or regulatory approvals.
Myovant Sciences: Becoming A Blockbuster
09:40am, Wednesday, 02'nd Jun 2021
Myovant recently cleared another regulatory binary for relugolix as a treatment for uterine fibroids. On top of the clearance for advanced prostate cancer, Relugolix is now approved for two indication
